Clinical-Stage Biotech Secures Capital Through Private Placements as Phase 2/3 Trials Advance in Ophthalmology and KRAS-Targeted Oncology
Multiple clinical-stage biotechnology companies are raising capital through private placements while advancing therapeutics toward FDA milestones in 2026-2027. Ocugen's OCU410 demonstrated 31% lesion reduction in geographic atrophy trials, while Silexion received approval to initiate Phase 2/3 testing of SIL204 for pancreatic cancer targeting KRAS mutations present in over 90% of cases.
Salvado•